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Abstract 
The aim of present study is to study the serum protein fingerprint of patients with colorectal 
cancer (CRC) and to screen protein molecules that are closely related to colorectal cancer 
during  the  onset  and  progression  of  the  disease  with  Matrix-assisted  laser  desorp-
tion/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Serum samples from 144 
patients with CRC and 120 healthy volunteers were adopted in present study. Weak cation 
exchange (WCX) magnetic beads and PBSII-C protein chips reader (Ciphergen Biosystems 
Ins.) were used. The protein fingerprint expression of all the Serum samples and the resulted 
profiles between cancer and normal groups were analyzed with Biomarker Wizard system. 
Several proteomic peaks were detected and four potential biomarkers with different ex-
pression profiles were identified with their relative molecular weights of 2870.7Da, 3084Da, 
9180.5Da, and 13748.8Da, respectively. Among the four proteins, two proteins with m/z 
2870.7 and 3084 were down-regulated, and the other two with m/z 9180.5 and 13748.8 were 
up-regulated in serum samples from CRC patients. The present diagnostic model could dis-
tinguish CRC from healthy controls with the sensitivity of 92.85% and the specificity of 
91.25%. Blind test data indicated a sensitivity of 86.95% and a specificity of 85%. The result 
suggested that MALDI technology could be used to screen critical proteins with differential 
expression in the serum of CRC patients. These differentially regulated proteins were con-
sidered as potential biomarkers for the patients with CRC in the serum and of the potential 
value for further investigation. 
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Introduction 
Colorectal cancer (CRC) is one leading cause of 
cancer death worldwide, with approximately 940 000 
new cases and 500 000 deaths reported annually [1]. 
Colorectal  cancer  is  also  the  second  most  common 
cancer in Europe [2.3]. Colorectal cancer was regarded 
as a multigenic disease and genetic abnormality plays 
a critical role in the development and progression of 
cancer cells besides the environmental factors [4]. The Int. J. Med. Sci. 2011, 8 
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five year survival rate for colorectal cancer diagnosed 
at early stages is higher than 90%, while the five year 
survival  rate  for  those  diagnosed  with  widespread 
cancer stage is less than 10% [5]. Mortality from CRC 
is  primarily  due  to  its  metastasis  to  the  liver,  ac-
counting for over 70% of death cases [6]. Surgical re-
section  currently  provides  the  best  way  of  cure. 
However, only 20% to 25% of CRC patients are eligi-
ble  for  surgery  treatments,  with  recurrence  rates 
range from 40% to 70 % [7, 8]. Early diagnosis of CRC 
is therefore of great importance. 
Currently the sensitivity of the single biomarker 
based CRC diagnosis is low and complicated with a 
high  probability  of  ‘false-positives’  cases.  Carci-
noembryonic antigen (CEA) is of proved benefits in 
prognosis and follow-up, but with limited sensitivity 
(30-40%)  for  early  CRC  diagnosis  [9].  It  should  be 
noted that none of these existed serum markers could 
be used individually for screening for CRC with suf-
ficient  accuracy  [30-34].  Endoscopic  examination  of 
the colon remains to be the gold standard for diagno-
sis, which is however invasive, unpleasant and carries 
associated risk of morbidity and mortality. Identifica-
tion  of  high-risk  patients  using  a  less  invasive  test 
would decrease the numbers of such procedures re-
quired. Serial feacal occult blood testing was proved 
to be useful but suffers from high false-negative and 
false-positive rates [10; 11]. Additionally, stool DNA 
analysis for multiple targets showed a sensitivity of 
71–91% in preliminary studies and larger studies were 
underway currently [12; 13]; however, a serum-based 
assay  with  equivalent  sensitivity  and  specificity 
would be more feasible and acceptable to many pa-
tients. 
A new method for diagnosing the early stage of 
CRC from serum samples is still an urgent need in 
clinical practice. In this study, we employed advanced 
proteomic approaches- Matrix-assisted laser desorp-
tion/ionization  time-of-flight  mass  spectrometry 
(MALDI-TOF-MS)  to  identify  relevant  biomarkers 
that could replace invasive and nonspecific tests for 
the early diagnosis of CRC. This is a relatively new 
technique, which is superior to 2D-gel-electrophoresis 
in proteomic research because of its high sensitivity 
for proteins in low molecular weight range and the 
capability  for  high  throughput  screening,  even  for 
proteins with extreme characteristics (highly hydro-
phobic, acidic or basic). In this technique, whole se-
rum  was  applied  onto  protein  chips  with  different 
chromatographic affinities in a suitable binding buf-
fer. Selectively bound proteins were retained on the 
surface  and  non-selectively  bound  proteins  were 
washed  off.  In  the  mass  spectrometer,  a  laser  de-
sorbed  the  bound  proteins  from  the  chip  surface, 
which  were  subsequently  detected  in  the  TOF  ana-
lyzer by their respective mass-to-charge ratios (m/z) 
[35, 36]. As whole patterns of proteins in the serum 
samples  were  analyzed,  more  than  one  biomarker 
would be detected. Combination of several biomark-
ers for the evaluation of a patient’s status could lead 
to enhanced sensitivity and specificity [37, 38, 39, 40, 
41]. 
In present study, we aimed to search differen-
tially  expressed  proteins  as  potential  biomarkers  in 
colorectal  cancer  patients  by  MALDI-TOF  MS.  We 
used WCX magnetic beads to screen potential serum 
biomarkers for colorectal cancer detection. A total of 
264  serum  samples  from  colorectal  cancer  patients 
and healthy volunteers was collected and analyzed. A 
panel of differentially expressed proteins was advo-
cated for biomarkers of diagnosis for colorectal can-
cer. 
Materials and methods 
Patients 
Experiment was performed in Taizhou Munici-
pal Hospital, Zhejiang, China in April 2010. Samples 
used were collected from 144 patients diagnosed with 
CRC  (ages  ranging  from  37-76)  and  120  controls 
(healthy  volunteers,  ages  ranging  from  33-68)  at 
Taizhou Municipal Hospital and The First Affiliated 
Hospital of Medical College, Zhejiang University. All 
CRC patients were diagnosed according to combined 
clinical criteria, including Endoscopic examination of 
the  colon,  a  combination  of  computed  tomography 
(CT), positron emission tomography (PET), or both, 
and further confirmed by histopathological analysis 
(Table  1).  The  studies  were  approved  by  the  local 
Ethics Committee of Taizhou Municipal Hospital, and 
had the informed consent of the patients and volun-
teers. The patients and serum samples were then di-
vided  into  two  groups:  the  ‘‘training’’  set  and  the 
blinded ‘‘test’’ set (Table 2).The blood samples were 
collected in 5 ml BD Vacutainers without anticoagu-
lation and allowed to clot at room temperature for up 
to 1 hr; the samples were then centrifuged at 4℃ for 5 
min at 10000 rpm. The sera were frozen and stored at 
-80℃ for future analysis. 
Table 1 Clinical Tumor-Node-Metastasis Stages of 144 
patients with CRC 
Stage  No. of patients (Training 
set) 
No. of patients (blind 
set) 
DUKES A  18  10 
DUKES B  44  22 
DUKES C  15  8 
DUKES D  21  6 
Total  98  46 Int. J. Med. Sci. 2011, 8 
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Table 2 Serum samples used in training and testing sets 
Samples  Training set  blind set  Total 
Colorectal cancer  98  46  144 
Healthy volunteers  80  40  120 
Total  178  86  264 
 
WCX magnetic beads analysis 
Sample pretreatments and proteomic analysis in 
the proteomic profiling analysis, the serum samples 
from  the  diseased  and  control  groups  were  rando-
mized, and blinded to investigators. Serum samples 
were  pretreated  with  weak  cation  exchange  (WCX) 
magnetic  beads  (SEDTM)  (Beijing  SED  Science  & 
Technology,  Inc.).  10  μl  of  each  serum  sample  was 
mixed with 20 μl of U9 solution (9 mol/L urea, 2% 
CHAPS, pH 9.0) in a 0.5 ml centrifuge-tube and in-
cubated for 30 min at 4℃. Denatured serum samples 
were diluted with 370 μl binding buffer (50 mmol/L 
sodium  acetate,  0.1%  Triton  X-100,  pH  4.0).  At  the 
same time, 50 μl of WCX magnetic beads were placed 
in a PCR-tube and the tube was placed in a magnet 
separator for 1 min, after which the supernatant was 
discarded carefully by using a pipette. The magnetic 
beads were then washed twice with 100 μl binding 
buffer. Then 100 μl of the diluted serum sample was 
added  to  the  activated  magnetic  beads,  mixed  and 
incubated for 1 h at 4℃, after which the beads were 
washed twice with 100 μl binding buffer.  
MALDI-TOF MS 
Following  binding  and  washing,  the  bound 
proteins were eluted from the magnetic beads using 
10  μl  of  0.5%  trifluoroacetic  acid.  Then,  5  μl  of  the 
eluted sample was diluted 1:2 fold in 5 μl of SPA (sa-
turated solution of sinapinic acid in 50% acetonitrile 
with 0.5% trifluoroacetic acid). Two microliters of the 
resulting mixture was aspirated and spotted onto the 
gold-coated ProteinChip array. After air-drying for 5 
minutes at room temperature, protein crystals on the 
chip were scanned with the ProteinChip (Model PBS 
IIc) reader (Ciphergen) to determine the masses and 
intensities of all peaks over the range m/z 1,000 to 
50,000. The reader was set up as follows: mass range 
(1,000 to 50,000 Daltons), optimized mass range (1,000 
to 20,000 Daltons), laser intensity (200), and sensitivity 
(9).  Mass  calibration  was  performed  using  an 
all-in-one peptide reference standard which contained 
vasopressin (1084.2Da), somatostatin (1637.9Da), bo-
vine insulin β chain (3495.9  Da), human insulin re-
combinant (5807.6Da), hirudin (7033.6Da) (Ciphergen 
Biosystems,  Fremont,  CA,  USA).  The  default  back-
ground subtraction was applied, and the peak inten-
sities  were  normalized  using  the  total  ion  current 
from a mass charge of 1000 to 50,000Da. A biomarker 
detection  software  package  (Ciphergen  Biomarker 
Wizards,  Ciphergen  Biosystems,  Inc)  was  used  to 
detect protein peaks (Figure 1).  
 
 
Figure 1. Spectra illustrating reproducibility of 4 separate analyses from the healthy controls of blood type O. It should be 
noted that the results were replicable and showed same protein peaks.  
 Int. J. Med. Sci. 2011, 8 
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Protein peaks were selected based on a first pass 
of signal-noise ratio of 3 and a minimum peak thre-
shold  of  20%  of  all  spectra.  This  process  was  com-
pleted with a second pass of peak selection at 0.2% of 
the  mass  window,  and  the  estimated  peaks  were 
added. These selected protein peaks were averaged as 
clusters and were exported to a commercially availa-
ble software package (Biomarker Patterns, Ciphergen 
Biosystems, Fremont, CA, USA) for further classifica-
tion analysis. 
Detection and Statistical Data Analysis  
The  data  were  analyzed  by  Ciphergen's  Pro-
teinChip  Software  (version  3.1).  When  the  differen-
tiated expressions of protein mass peak were found 
between the groups of colorectal cancer and healthy 
controls, these data in the Excel format were imported 
into the Biomarker Pattern Software (BPS) to construct 
the  classification  tree  of  CRC.  The  significantly  dif-
ferent expression of protein mass peaks (P < 0.01) was 
listed  by  the  software.  Subsequently,  the  differen-
tiated  expressions  of  protein  mass  peak  were  ana-
lyzed by discriminatory analysis. Briefly, the dataset 
formed a "root node". The software tried to find the 
best  peak  to  separate  this  dataset  into  two  "child 
nodes" based on peak intensity. To achieve this, the 
software would identify the best peak and set a peak 
intensity  threshold.  If  the  peak  intensity  of  a  blind 
sample was lower than or equal to the threshold, this 
peak would go to the left-side child node. Otherwise, 
the peak would go to the right-side child node. After 
rounds of decision making, the training set was found 
to be discriminatory with the least error. 
All  the  results  were  expressed  as  mean±S.D., 
and P values < 0.01 were considered statistically sig-
nificant. Sensitivity was calculated as the ratio of the 
number of correctly classified diseased samples to the 
total  number  of  diseased  samples.  Specificity  was 
calculated  as  the  ratio  of  the  number  of  negative 
samples correctly classified to the total number of true 
negative samples. 
Results 
Detection of the Protein Peaks 
Proteomic data from the samples of the training 
set (consisting of 98 CRC and 80 controls) were ana-
lyzed with Biomarker Wizard software 3.1. Up to 252 
protein peaks per spot were detected between m/z 
1000 and m/z 50000 and this proved the effectiveness 
of the MALDI technology in separated detection of 
low molecular weight proteins (<2 0000) (Figure 2, 3). 
Additionally, we compared the spectrums from pa-
tients in different stages of CRC to evaluate the con-
sistency of these biomarkers in early diagnosis. Inte-
restingly  we  found  that  in  serum  from  early  stage 
patients at DUKES A showed two more m/z peaks at 
6111 and 7978, which would diminish in serum sam-
ples from later stage patients (B, C, D) (Figure 4). 
Protein Fingerprint Analysis of Serum Samples 
in Patients with CRC and Healthy Controls  
The protein profile of the serum samples from 
the 98 patients with CRC and the 80 healthy controls 
were extracted by magnetic beads and examined by 
MALDI-TOF-MS.  The  data  were  analyzed  by  Bio-
marker Wizard Version 3.1; 68 m/z peaks were found 
to  discriminate  the  patients  with  CRC  and  healthy 
controls  (Table  3).  We  were  able  to  simultaneously 
analyze the protein profiles of 90 serum samples from 
both CRC patients and healthy volunteers. We identi-
fied several biomarkers specific for CRC (Figure 2, 3).
 
 
 
 
Figure 2. Representative protein spectrum of 2 separate analyses from CRC patient and control by MALDI-TOF MS 
combined with WCX magnetic beads, showing the protein m/z between 1000 and 20000. The figure showed some different 
peaks on the spectrum.  Int. J. Med. Sci. 2011, 8 
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Figure 3. Differential expression of MALDI peak m/z 2870.7, 3084, 9180.5, 13748.8 in CRC and control sera. Each peak 
were represented by three control and three patient samples. The arrow indicated the peak difference.  
 
 
 
Figure 4. The representative m/z peaks at 6111 and 7978 in different stage CRC patients with DUKES A and Patients with 
DUKES B DUKES C and DUKES D. This data suggested that in different stages of CRC patients, there could be differential 
regulation of biomarkers, and some of them could diminish in late stages.  
 
Four  peaks,  m/z  2870.7Da,  3084Da,  9180.5Da, 
13748.8Da were then chosen to set up the decision tree 
[24-25] (Figure 5). At Node l, samples of m/z 9180.5 
with peak intensities lower than or equal to 6.28 went 
to terminal Node 1, which had 45 healthy volunteer. 
Otherwise,  samples  entered  Node  2,  which  had  35 
healthy volunteers and 98 CRC samples. At Node 2, 
samples of m/z 3084 with peak intensities lower than 
or equal to 1.89 went to Node 3, which had 10 healthy 
volunteers and 80 CRC samples. The other samples 
entered terminal Node 4, which had 18 CRC samples 
and 25 healthy volunteers. At Node 3, samples of m/z Int. J. Med. Sci. 2011, 8 
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2870.7  with  peak  intensities  lower  than  or  equal  to 
4.08 went to terminal Node 2, which had 2 healthy 
volunteer  samples  and  76  CRC.  The  other  samples 
went to terminal Node 3, which had 8 healthy volun-
teer samples and 4 CRC. At Node 4, samples of m/z 
13748.8 with peak intensities lower than or equal to 
5.06 went to terminal Node 4, which had 20 healthy 
volunteer samples and 3 CRC. The other samples en-
tered terminal Node 5, which had 5 healthy volunteer 
samples and 15 CRC samples (Figure 5). 
 
Table 3 The 68 discriminating m/z peaks among CRC and normal controls 
m/z  p  m/z  p  m/z  p  m/z  p  m/z  p 
5635.3  2.0×10-8  11513.2  3.2×10-6  4599.1  1.2×10-5  9498.9  6.8×10-5  4112.6  8.6×10-4 
4284.5  4.2×10-8  13748.8*  3.5×10-6  6837.5  1.5×10-5  23415.8  7.9×10-5  4159.9  8.9×10-4 
2870. 7*  4.9×10-8  2915.8  4.6×10-6  2949.1  1.9×10-5  2744.9  2.5×10-4  7628.5  9.1×10-4 
4476.5  7.3×10-8  5910.8  5.1×10-6  3400.7  2.1×10-5  2800.6  3.6×10-4  6435.3  9.5×10-4 
9180.5*  1.5×10-7  5703.4  5.8×10-6  3817.5  2.3×10-5  3377.9  4.5×10-4  7564.4  0.001 
2894.6  2.2×10-7  3320.4  6.3×10-6  5905.1  2.4×10-5  6361. 8  5.1×10-4  3692.4  0.001 
3084*  4.5×10-7  3975.31  6.8×10-6  3219.4  2.9×10-5  14784.8  5.5×10-4  7839.8  0.001 
4452.9  5.8×10-7  4647.4  7.1×10-6  6194.6  3.3×10-5  18378.9  5.7×10-4  9342.9  0.002 
5213  6.4×10-7  9286.1  7.4×10-6  4703.3  3.8×10-5  4387.29  5.8×10-4  24092.6  0.004 
4945.9  8.8×10-7  2152.5  8.9×10-6  2686.1  4.1×10-5  4350.5  6.5×10-4  4299.3  0.004 
9713.5  9.8×10-7  15114.2  9.2×10-6  5545.4  4.5×10-5  5479.3  6.6×10-4  7941  0.006 
8564.3  9.9×10-7  2545.7  9.4×10-6  13270.1  4.6×10-5  11076.0  7.0×10-4  15309  0.009 
5809.6  1.1×10-6  8146.1  9.6×10-6  4985.2  6.2×10-5  6883.3  7.5×10-4  2821.5  0.009 
3089.7  2.0×10-7  2756.8  9.9×10-6  5504.8  6.3×10-5  N/A  N/A  N/A  N/A 
m/z means mass-to-charge ratio. P was generated by peak comparison between CRC and normal controls. Peaks labeled by * were selected 
as biomarkers for CRC diagnostic model. 
 
 
 
Figure 5. The decision trees of diagnostic model for CRC. Each node was represented with different m/z value and the 
diagnosis result went left or right depending on the detected peaks in test sample. The sensitivity and specificity of diagnosis 
would significantly increase when several biomarkers were combined in use. Int. J. Med. Sci. 2011, 8 
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Identification of Biomarker Pattern and Con-
struction of Diagnostic Model  
The decision tree could differentiate samples of 
CRC  and  healthy  controls.  Here,  we  used  the  bio-
marker wizard function of the ProteinChip software 
to identify clusters of peaks differentially presented in 
CRC serum samples compared with healthy controls. 
We  obtained  68  different  protein  peaks  in  sera 
(showed in Table 3). To develop biomarker patterns 
for the diagnosis of CRC, the intensities of the protein 
peaks in the training set were submitted to BPS. A 
total of four peaks (2870.7, 3084, 9180.5, 13748.8) with 
the highest discriminatory power were automatically 
selected  to  construct  a  classification  tree  (Figure  5). 
Figure 5 shows the tree structure and sample distri-
bution. The classification tree using the combination 
of the four peaks identified 98 CRC and 80 healthy 
controls with a calculated sensitivity of 92.85% and a 
specificity of 91.25%. In the blind test set, 34 out of 40 
true control cases were correctly classified, and 40 out 
of 46 CRC samples were correctly classified as ma-
lignant. These results yield a sensitivity of 86.95% and 
a specificity of 85% (Table 4). 
 
Table 4 The prediction results of the diagnostic model for 
CRC 
Group  Samples  Cases  Correct-classed  Accurate % 
Training set  CRC  98  91  92.85 
  control  80  73  91.25 
Blinding set  CRC  46  40  86.95 
  control  40  34  85 
 
Discussion 
Mass spectrometry proteomics suggests that it is 
possible to detect molecular changes before the tumor 
is palpable. This technique has an important role in 
the diagnosis and monitoring of tumor progression. 
MALDI-TOF-MS is a newly-developed technique to 
evaluate proteins separately in past decade The WCX 
magnetic  beads  have  established  the  expression  of 
tumor protein in the serum specimens including lung, 
breast, and gastric cancer. Some of the proteins from 
magnetic  beads  have  become  the  newly  discovered 
markers for tumor diagnosis, with higher sensitivity 
and specificity than the former markers [14-18]. Cur-
rently,  there  are  many  noninvasive  diagnostic  me-
thods  of  colorectal  cancer  such  as  the  fecal  occult 
blood  test,  the  serum  markers  (e.g.,  CA199,  CEA), 
immunologic and biochemistry test. But, the sensitiv-
ity and specificity of the current biomarkers in tumor 
diagnosis is low (usually less than 70%) and compli-
cated  by  high  return  of  ‘false-positives’  and  ‘false 
negatives’ [19]. The data in this paper supported these 
past  studies.  These  identified  potential  biomarkers 
would require validation with large numbers of pa-
tients, and if successful, could point to the develop-
ment  of  more  widely  applicable  immunoassays. 
Moreover, this is sensitive enough to early stage CRC 
detection,  suggesting  its  prospective  application  in 
early diagnosis of CRC. 
It is possible now to find new tumor markers for 
diagnosing  and  monitoring  the  occurrence  and  de-
velopment  of  tumors  given  the  progresses  that  the 
proteomics  tools  have  achieved  [20].  Some  studies 
identified several potential biomarkers for CRC with 
these tools, but lack enough specificity and sensitivity 
[30-34].  Matrix-assisted  laser  desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) is 
one useful tool for integrating separation and analysis 
of complex mixtures of proteins. Captured proteins 
are then analyzed by TOF-MS, generating a spectral 
map  depicting  approximations  of  the  molecular 
weight (m/z) and relative concentration (intensity) of 
each protein (ion). WCX magnetic beads could cap-
ture more proteins in serum than strong anionic ex-
change magnetic beads, especially in the low mole-
cular weight range. It has been extensively applied to 
the researches about tumor markers [21.22], such as 
prostate cancer [23.24], breast carcinoma [25], bladder 
cancer [26], hepatocellular carcinoma [27], nasopha-
ryngeal cancer [28, 42] and so on [29]. The initial se-
rum  proteome  profiles  of  CRC  were  generated  by 
using the combination of MALDI-TOF MS and WCX 
magnetic  beads  as  well  as  pattern  recognition  soft-
ware  in  our  study.  The  68  different  protein  peaks 
between CRC and control subjects suggested that the 
broad  pathological  changes  occurred  in  serum 
proteome of CRC patients, though unidentified pro-
teins may also be involved.  
In conclusion, MALDI-TOF MS combined with 
magnetic beads is one useful tool for integrating se-
paration  and  analysis  of  complex  mixtures  of  pro-
teins. With the panel of four selected biomarkers, we 
achieved high sensitivity and specificity for the de-
tection of CRC. It should be noted that in this study 
each  M/Z  value  may  represent  many  peptides  of 
similar molecular weights. We expect to explore the 
structure and function of these protein biomarkers for 
CRC in future studies.  
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